Cantor Fitzgerald Comments on Arcellx FY2025 Earnings

Arcellx, Inc. (NASDAQ:ACLX) – Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for Arcellx in a research note issued on Monday, August 4th. Cantor Fitzgerald analyst E. Schmidt forecasts that the company will earn ($2.98) per share for the year. Cantor Fitzgerald has a “Strong-Buy” rating on the stock. The consensus estimate for Arcellx’s current full-year earnings is ($1.58) per share. Cantor Fitzgerald also issued estimates for Arcellx’s FY2026 earnings at ($2.65) EPS.

Arcellx (NASDAQ:ACLX) last posted its quarterly earnings results on Thursday, May 8th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.84) by ($0.29). The business had revenue of $8.13 million during the quarter, compared to analyst estimates of $19.51 million. Arcellx had a negative return on equity of 35.27% and a negative net margin of 211.46%.

Other analysts have also recently issued reports about the stock. Citigroup initiated coverage on shares of Arcellx in a research note on Tuesday, June 17th. They set a “buy” rating and a $110.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $115.00 price objective on shares of Arcellx in a research note on Monday, June 16th. Finally, Scotiabank upped their price objective on shares of Arcellx from $93.00 to $133.00 and gave the stock a “sector outperform” rating in a research note on Thursday, July 31st. Thirteen equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, Arcellx currently has an average rating of “Buy” and a consensus price target of $114.31.

Arcellx Trading Down 1.9%

Shares of Arcellx stock opened at $70.67 on Wednesday. The stock has a market capitalization of $3.89 billion, a price-to-earnings ratio of -23.64 and a beta of 0.28. Arcellx has a 1-year low of $47.86 and a 1-year high of $107.37. The firm’s 50-day moving average price is $67.23 and its two-hundred day moving average price is $65.15.

Hedge Funds Weigh In On Arcellx

Several large investors have recently bought and sold shares of ACLX. Gilead Sciences Inc. acquired a new position in Arcellx in the fourth quarter valued at approximately $515,418,000. Vestal Point Capital LP lifted its holdings in Arcellx by 402.7% in the first quarter. Vestal Point Capital LP now owns 2,387,720 shares of the company’s stock valued at $156,634,000 after buying an additional 1,912,720 shares during the period. FMR LLC lifted its holdings in Arcellx by 22.8% in the fourth quarter. FMR LLC now owns 7,956,633 shares of the company’s stock valued at $610,194,000 after buying an additional 1,477,360 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in Arcellx by 135.9% in the first quarter. T. Rowe Price Investment Management Inc. now owns 1,665,138 shares of the company’s stock valued at $109,234,000 after buying an additional 959,216 shares during the period. Finally, RA Capital Management L.P. lifted its holdings in Arcellx by 50.5% in the fourth quarter. RA Capital Management L.P. now owns 2,787,327 shares of the company’s stock valued at $213,760,000 after buying an additional 935,848 shares during the period. 96.03% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Arcellx

In other news, Director Kavita Patel sold 1,500 shares of the stock in a transaction that occurred on Tuesday, June 10th. The shares were sold at an average price of $67.36, for a total transaction of $101,040.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. 8.35% of the stock is owned by company insiders.

Arcellx Company Profile

Arcellx, Inc, together with its subsidiary, engages in the development of various immunotherapies for patients with cancer and other incurable diseases in the United States. The company’s lead ddCAR product candidate is anitocabtagene autoleucel, which is in phase 2 clinical trial for the treatment of patients with relapsed or refractory multiple myeloma (rrMM).